L-dopa treatment of parkinsonism. Clinical observations on the use of amantadine hydrochloride.
D000368:Aged; D000547:Amantadine / Q000009:adverse effects / Q000627:therapeutic use*; D002712:Chlorides / Q000627:therapeutic use; D003863:Depression / Q000139:chemically induced; D004295:Dihydroxyphenylalanine / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D004342:Drug Hypersensitivity; D005260:Female; D005500:Follow-Up Studies; D006212:Hallucinations / Q000139:chemically induced; D006801:Humans; D006948:Hyperkinesis / Q000139:chemically induced; D006993:Hypnotics and Sedatives / Q000494:pharmacology; D007022:Hypotension / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010276:Parasympatholytics / Q000494:pharmacology; D010300:Parkinson Disease / Q000188:drug therapy*; D013566:Sympathomimetics / Q000494:pharmacology; D014839:Vomiting / Q000139:chemically induced
D002712:Chlorides; D006993:Hypnotics and Sedatives; D010276:Parasympatholytics; D013566:Sympathomimetics; D004295:Dihydroxyphenylalanine; D000547:Amantadine